AYTU BIOPHARMA, INC AYTU
Aytu BioPharma, Inc. ("Aytu," the "Company," "we," "us," or "our") is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the "Nasdaq") under the ticker symbol "AYTU." Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $7.3M | $3.7M | $3.2M | $2.6M |
| Cost of revenue | $20.6M | $16.1M | $40.8M | $44.4M | $36.4M | $8.3M | $2.2M | $2.1M | $1.4M | $957.1K |
| Gross profit | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M | $19.4M | $5.1M | $1.6M | $1.8M | $1.6M |
| R&D | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M | $1.7M | $589.1K | $167.6K | $959.9K | $6.1M |
| SG&A | $17.4M | $20.0M | $28.6M | $31.2M | $25.5M | $19.7M | $18.9M | $17.7M | $17.4M | $8.5M |
| Total operating expenses | $53.7M | $50.6M | $83.7M | $162.2M | $88.1M | $40.5M | $24.2M | $23.4M | $23.3M | $24.3M |
| Operating income | -$7.8M | -$1.6M | -$17.1M | -$109.9M | -$58.9M | -$21.1M | -$16.8M | -$19.7M | -$20.1M | -$21.7M |
| Interest expense | $3.7M | $5.1M | $5.0M | — | — | $2.6M | $535.5K | $749.4K | $2.5M | $5.5M |
| Pre-tax income | -$13.7M | -$10.4M | -$17.1M | -$108.9M | -$58.0M | -$13.6M | -$27.1M | -$10.2M | -$22.5M | -$28.2M |
| Income tax | $437.0K | $2.1M | $0 | $110.0K | $259.0K | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.6M | -$15.8M | -$17.1M | -$108.8M | -$58.3M | -$13.6M | -$27.1M | -$10.2M | -$22.5M | -$28.2M |
| EPS, basic | -2.16 | -2.86 | -5.11 | -74.01 | -3.48 | — | — | — | — | — |
| EPS, diluted | — | — | -5.11 | -74.01 | -3.48 | -3.01 | -3.48 | -15.31 | -48.30 | -323.70 |
| Shares, diluted (wtd. avg.) | $6.3M | $5.5M | $3.3M | $1.5M | $16.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $31.0M | $20.0M | $23.0M | $19.4M | $49.9M | $48.3M | $11.0M | $7.0M | $802.3K | $8.1M |
| Short-term investments | — | — | — | — | — | — | — | — | $0 | $1.0M |
| Receivables | $31.2M | $23.5M | $28.9M | $21.7M | $28.2M | $5.6M | $1.7M | $578.8K | $528.0K | $162.4K |
| Inventory | $11.4M | $12.1M | $12.0M | $10.8M | $16.3M | $10.0M | $1.4M | $1.3M | $1.3M | $524.7K |
| Total current assets | $79.2M | $61.9M | $72.8M | $59.9M | $105.2M | $75.4M | $15.4M | $9.5M | $3.0M | $10.1M |
| Property, plant and equipment | $532.0K | $693.0K | $1.8M | — | — | $258.5K | $203.7K | $218.7K | $647.3K | $231.4K |
| Goodwill | — | — | $0 | $0 | $65.8M | $28.1M | $0 | — | $238.4K | $221.0K |
| Other intangibles | $42.2M | $52.5M | $59.0M | $70.6M | $85.5M | $48.9M | $19.1M | $245.9K | $271.3K | $296.6K |
| Total assets | $124.2M | $118.1M | $136.5M | $137.6M | $265.7M | $153.3M | $34.7M | $21.1M | $15.0M | $24.3M |
| Accounts payable | $10.6M | $10.3M | $13.5M | — | $19.3M | $11.6M | $2.1M | $2.1M | $2.2M | $2.3M |
| Short-term debt | $1.9M | $1.9M | $85.0K | $3.8M | — | $982.1K | $0 | — | — | — |
| Total current liabilities | $63.1M | $62.2M | $69.0M | $64.4M | $109.4M | $28.8M | $5.4M | $3.4M | $3.6M | $10.1M |
| Long-term debt | $10.9M | $10.9M | $14.7M | $15.0M | — | — | — | — | — | — |
| Total liabilities | — | — | $97.1M | $93.3M | $128.1M | $58.3M | $27.6M | $7.6M | $11.0M | $14.3M |
| Retained earnings | -$333.5M | -$320.0M | -$304.1M | -$287.1M | -$178.3M | -$120.0M | -$106.4M | -$79.3M | -$69.1M | -$46.6M |
| Total equity | $19.0M | $27.7M | $39.4M | $44.3M | $137.6M | $95.0M | $7.1M | $13.4M | $4.0M | $10.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$1.4M | -$5.1M | -$28.8M | -$26.0M | -$28.4M | -$13.8M | -$15.9M | -$13.8M | -$10.7M |
| Depreciation and amortisation | $5.4M | $6.7M | $8.8M | $10.1M | $9.2M | $5.7M | $2.7M | $2.6M | $4.4M | $874.8K |
| Stock-based compensation | $576.0K | $2.4M | $6.0M | $5.2M | $3.6M | $1.1M | $1.0M | $596.9K | $2.5M | $902.9K |
| Capital expenditure | $228.0K | $329.0K | — | $0 | $2.3M | $0 | $59.8K | $74.7K | $111.6K | $252.9K |
| Investing cash flow | -$2.6M | -$329.0K | -$117.0K | -$3.2M | -$2.8M | -$5.7M | -$1.1M | -$484.3K | -$3.5M | -$5.3M |
| Financing cash flow | $15.4M | -$1.3M | $8.9M | $1.5M | $30.3M | $71.1M | $19.1M | $22.7M | $10.2M | $16.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-25-029723.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |